ASCO: New Advances in Ovarian, Prostate, Lung and Melanoma Treatment

SOG_5604_10SMALL

“Science and Society” was the theme of this year’s American Society of Clinical Oncology (ASCO) 50th annual meeting. The meeting showcased  cancer research from around the world. Some new findings from Dana-Farber researchers included: Joyce Liu, MD, MPH, of the Susan F. Smith Center for Women’s Cancers reported that, in a phase 2 clinical trial, a combination of olaparib (a drug that blocks DNA repair in cancer cells) and cediranib (which blocks blood vessel growth in tumors) was considerably more effective in women with recurrent ovarian cancer than olaparib alone.. Progression-free survival – the length of time after treatment when …

Continue reading

Five Things You Need to Know About Men’s Health/Cancer Screenings

SOG_7048_12

Cancer affects thousands of men across the United States every year, with the most common diagnoses coming in the form of prostate, colon, testicular, lung, and skin cancer. Not all cancers can be detected early on, but for some forms of the disease, the spread of cancer can be prevented through screenings. As June marks Men’s Health/Cancer Awareness Month, here are five things you need to know about men’s health screenings:   1. Prostate Cancer One in every six men is affected by prostate cancer, which most often affects men over age 50. In addition, age, family history, diet and lifestyle, …

Continue reading

Precision Medicine for Lung Cancer Marks Tenth Anniversary

4.30.14 Lung CancerSmall

Ten years ago researchers at Dana-Farber and in Japan published a study showing that lung cancer patients whose tumors had a malfunctioning version of a protein called Epidermal Growth Factor Receptor (EGFR) responded dramatically to a drug that specifically targets the EGFR protein. The findings launched the era of precision medicine for lung cancer, transforming the way the disease is treated in many patients. Today, the arsenal of targeted therapies for lung adenocarcioma – the most common lung malignancy – includes more than a dozen agents, some of which have received Food and Drug Administration (FDA) approval and some of …

Continue reading

CVS to Rid Shelves of Tobacco Products: A ‘Powerful Signal’

CVS Caremark announced this week it will stop selling cigarettes and tobacco products in order to promote the health and well-being of its customers. The new policy will take effect October 1, 2014. “This step sends a powerful signal that tobacco products have no place at a retail organization dedicated to health,” says Dana-Farber President Edward J. Benz, Jr., MD. “We hope that other retailers will see the enormous contribution they could make to the nation’s health if they were to join CVS in ridding their shelves of these products.”

Top 10 Insight Stories from 2013

As 2013 comes to a close, we’re looking back at some of our favorite Insight posts from the last year. From inspiring patient stories to important research, here is our top 10 list:

Fighting the Lung Cancer Stigma

Despite the research, the promising new drugs, the many ongoing clinical trials, lung cancer remains a disease that affects too many people, too often. For patients and family members, the disease carries an added burden: a stigma that lung cancer and smoking go hand in hand, and that lung cancer patients brought this on themselves. Not only must these patients and family members face their disease, but they also must carry the guilt and blame that some people cast their way. When we posted a recent infographic on smoking and cancer, we unintentionally helped promote that stigma. We’re deeply sorry …

Continue reading

Lung Cancer: Five Things You Need to Know

More than 228,000 new cases of lung cancer will be diagnosed in the United States in 2013, according to the National Cancer Institute (NCI). With November marking Lung Cancer Awareness Month, Pasi A. Jänne, MD, PhD, director of Dana-Farber’s Lowe Center for Thoracic Oncology, answers some key questions about the disease: